North Yelm, WA, United States
North Yelm, WA, United States

Time filter

Source Type

Ramamoorthi R.,BIO Ventures for Global Health | Graef K.M.,BIO Ventures for Global Health | Dent J.,BIO Ventures for Global Health
International Journal for Parasitology: Drugs and Drug Resistance | Year: 2014

Neglected tropical diseases (NTDs), malaria, and tuberculosis have a devastating effect on an estimated 1.6. billion people worldwide. The World Intellectual Property Organization (WIPO) Re:Search consortium accelerates the development of new drugs, vaccines, and diagnostics for these diseases by connecting the assets and resources of pharmaceutical companies, such as compound libraries and expertise, to academic or nonprofit researchers with novel product discovery or development ideas. As the WIPO Re:Search Partnership Hub Administrator, BIO Ventures for Global Health (BVGH) fields requests from researchers, identifies Member organizations able to fulfill these requests, and helps forge mutually beneficial collaborations. Since its inception in October 2011, WIPO Re:Search membership has expanded to more than 90 institutions, including leading pharmaceutical companies, universities, nonprofit research institutions, and product development partnerships from around the world. To date, WIPO Re:Search has facilitated over 70 research agreements between Consortium Members, including 11 collaborations focused on anthelmintic drug discovery. © 2014 Australian Society for Parasitology.


Ramamoorthi R.,BIO Ventures for Global Health | Graef K.M.,BIO Ventures for Global Health | Krattiger A.,World Intellectual Property Organization | Dent J.C.,BIO Ventures for Global Health
Chemical Reviews | Year: 2014

The World Intellectual Property Organization (WIPO), BIO Ventures for Global Health (BVGH), and eight leading pharmaceutical companies, Alnylam, AstraZeneca, Eisai, GlaxoSmithKline (GSK), MSD, Novartis, Pfizer, and Sanofi joined forces to establish the WIPO Re:Search consortium. WIPO Re:Search seeks to accelerate the development of new drugs, vaccines, and diagnostics for NTDs, malaria, and tuberculosis by connecting the resources of private industry to academic and nonprofit researchers with novel product discovery or development ideas for these diseases. Through WIPO Re:Search, researchers are exploring how natural products may lead to the development of novel tuberculosis treatments. Researchers at the National Institute of Immunology (NII) in New Delhi, India, are utilizing the GSK PKIS1 to examine the essential molecular mechanisms of M. tuberculosis cell wall synthesis. By providing nonprofit and academic researchers working on neglected diseases with the opportunity to access compounds and expertise from pharmaceutical companies, WIPO Re:Search is opening new doors and creating additional avenues for product development for diseases of poverty.


Ramamoorthi R.,BIO Ventures for Global Health | Graef K.M.,BIO Ventures for Global Health | Dent J.,BIO Ventures for Global Health
Future Medicinal Chemistry | Year: 2015

Schistosomiasis, one of 17 diseases deemed to be neglected by the World Health Organization, has received little attention from the biopharmaceutical industry. Due to this, only a handful of drugs have been developed to treat schistosomiasis, with only one, praziquantel, used in most endemic regions. Growing concern over resistance coupled with praziquantel's incomplete efficacy across all stages of the Schistosoma platyhelminth life cycle highlights the urgent need for new drugs. The WIPO Re:Search consortium is a platform whereupon biopharmaceutical company compounds are being repurposed to efficiently and cost-effectively develop new drugs for neglected diseases such as schistosomiasis. This article summarizes recent clinical-stage efforts to identify new antischistosomals and highlights biopharmaceutical company compounds with potential for repurposing to treat schistosomiasis. © 2015 Future Science Ltd.

Loading BIO Ventures for Global Health collaborators
Loading BIO Ventures for Global Health collaborators